Full-Time
Confirmed live in the last 24 hours
Provides analytics and decision tools for professionals
Junior, Mid
Company Historically Provides H1B Sponsorship
Houston, TX, USA
The position will require 2 days per week in our Houston, TX office.
You match the following RELX's candidate preferences
Employers are more likely to interview you if you match these preferences:
RELX provides information-based analytics and decision tools tailored for professional and business customers across various sectors. The company operates in four key areas: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products utilize extensive data and analytics to assist clients, such as researchers, healthcare professionals, legal practitioners, and business executives, in making informed decisions and enhancing productivity. RELX distinguishes itself from competitors through its subscription-based business model, which ensures a consistent revenue stream, alongside income from transactional sales and advertising. The company's goal is to support corporate responsibility initiatives, focusing on diversity, social justice, and sustainable development, while actively contributing to the United Nations' Sustainable Development Goals (SDGs) through its offerings.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
1894
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Family Planning Benefits
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Remote Work Options
Digital Health Data Insights are Needed at Scale for Life Insurers to Continue to Reach UnderservedMarkets, Close the Life Insurance Gap and Reduce Mortality SlippageATLANTA, Feb. 20, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions today announced continued innovation of LexisNexis® Health Intelligence, its digital health data platform for the U.S. life insurance industry. The platform provides information and insights, including a concise and simplified clinical history report; leverages advanced linking, parsing and normalization; and helps life insurers scale their use of electronic health records (EHRs). These new innovations empower life insurance carriers with access to digital health data, sourced from EHRs, and advanced analytics that enable faster, more friction-free interactions for life insurance applicants, helping to streamline the underwriting workflow.Deriving insights from digital health data is critical to address life insurers' needs for future transformation and to achieve their objectives to close the coverage gap for un- or under-insured individuals, while minimizing mortality slippage and delivering a simplified buying experience. When LexisNexis Risk Solutions acquired the Human API Health Intelligence platform, it included a robust network of health data sources, a consumer consent management experience, as well as capabilities to ensure a consistent deliverable for life insurers that use EHRs in the underwriting process
Blended, patient-level datasets leveraging proprietary tokenization technology simplify data enrichment while adhering to privacy standards. ATLANTA, Jan. 29, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions, a leading provider of healthcare analytics and insights, today announced the launch of new research-ready, real-world datasets designed to accelerate research timelines, reduce costs and enable more equitable analyses. Using referential-based tokenization, the patient-level datasets are blended, expert determined and certified ensuring they are standardized and research ready. This process gives research teams a more simplified way to enrich their datasets or define a cohort of interest to support specific study objectives, including benchmarking with comparator cohorts. These datasets integrate into clinical research workflows, generating impactful real-world evidence to accelerate innovation and speed-to-market
Mr. Whayman’s previous leadership roles at the company include serving as Chief Financial Officer, Chief Commercial Officer and Managing Director of the Researchers and Librarians business segmentLondon, January 14, 2025. Elsevier, a global leader in scientific information and analytics, announced today the appointment of Stuart Whayman as President of Corporate Markets effective January 6, 2025. Mr. Whayman will report to Kumsal Bayazit, CEO of Elsevier, and will lead the global business that provides advanced scientific and technical information, data and decision support solutions for innovation to R&D-focused organizations across various industries, including pharmaceuticals and chemicals.Mr. Whayman joined Elsevier in 2014, initially as Chief Financial Officer and later served as Chief Commercial Officer
SINGAPORE, Dec 5, 2024 - (ACN Newswire) - inter airport Southeast Asia, the premier trade exhibition and conference for airport innovation and technology in Asia, will return to Singapore from 25 to 27 March 2025 at the Marina Bay Sands. The 8th edition is expected to bring together over 3,500 representatives of the aviation industry in Asia, influencers in the airports and airlines community, and 150+ exhibitors, including world-class solution providers and airport equipment suppliers, to connect, find synergies, build partnerships, and innovate. As the aviation industry advances and new airport projects and investments surge globally, groundbreaking innovations are essential to drive its transformation. Themed “Airport Operations for Tomorrow” conversations at the exhibition and conference will highlight innovation, technology, and sustainable solutions to optimise terminal and ramp operations of the future. Asia driving majority in airport projects
Access to Enamine’s novel compounds will allow Reaxys users to cut development times and costs by up to 90%. London, 3 December 2024 – Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine’s database of over 43 million make-on-demand (MADE) analog compounds into Reaxys. The integration will provide chemists with unparalleled access to a diverse array of chemical compounds for accelerated drug discovery and materials science research. Reaxys is a leading chemical database that combines over a billion chemistry data points from scientific journals and patents with AI to support innovation in drug discovery, chemical RD and academia. This new integration combines Enamine's expertise in compound synthesis with the comprehensive capabilities of the Reaxys platform, enabling researchers to access a vast repository of chemical information and facilitating the identification of novel drug targets, biomarkers, and screening compounds